May 30, 2016
Findings presented at the ASH Annual Meeting and Exposition contribute to the growing body of literature that demonstrates a correlation between specific gene mutations and prognosis among patients with acute myeloid leukemia and myelodysplastic syndrome. Opinions are mixed in regard to how the evidence could impact scoring systems used to classify patients, which currently do not consider these mutations, but experts agree that the evidence promotes the development of new therapeutic agents.
“There is a wealth of emerging information that demonstrates that specific mutations in MDS are associated with prognosis, inside and outside the context of allogeneic hematopoietic stem cell transplantation,” William A. Wood, MD, of the Leukemia, Lymphoma and Myeloma Program and the Bone Marrow and Stem Cell Transplantation Program at the University of North Carolina School of Medicine, told Healio.com. “Further, the presence of these mutations may contribute independent prognostic information in addition to what is already known through the most commonly used prognostic scoring systems in this disease.”